Opinion Dynamics Systems via Biswas–Chatterjee–Sen Model on Solomon Networks

Autor: Edmundo Alves Filho, Francisco Welington Lima, Tayroni Francisco Alencar Alves, Gladstone de Alencar Alves, Joao Antonio Plascak

Publikováno v: Physics, Vol 5, Iss 3, Pp 873-882 (2023)

The critical properties of a discrete version of opinion dynamics systems, based on the Biswas–Chatterjee–Sen model defined on Solomon networks with both nearest and random neighbors, are investigated through extensive computer simulations. By em

Externí odkaz: https://doaj.org/article/39029f82523f44d69cfcf2d19fc30897

The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment.

Autor: Komlodi-Pasztor E; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, United States., Escarra-Senmarti M; Department of Pathology, Division of Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Bazer DA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Bhatnagar A; Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, United States., Perez Heydrich CA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Messmer M; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States., Ambinder RF; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Gladstone DE; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Northwell Health Cancer Institute, New Hyde Park, NY, United States., Clayton L; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Goodrich A; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Schoch L; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Wagner-Johnston N; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., VandenBussche CJ; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Pathology, Division of Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Huang P; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Holdhoff M; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Rosario M; Department of Pathology, Division of Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2024 Sep 04; Vol. 15, pp. 1433442. Date of Electronic Publication: 2024 Sep 04 (Print Publication: 2024).

Immune-related encephalitis after immune checkpoint inhibitor therapy.

Autor: Buckley MW; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.; Department of Neurology, University of Virginia School of Medicine, Charlottesville, VA 22903, United States., Balaji Warner A; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, United States., Brahmer J; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, United States., Cappelli LC; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States., Sharfman WH; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, United States., Fuchs E; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States., Kang H; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.; Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, United States., Forde PM; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, United States., Gladstone DE; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.; R.J. Zuckerberg Cancer Center at Hofstra/Northwell Health, Lake Success, NY 11042, United States., Ambinder R; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States., Kelly RJ; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.; Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX 75246, United States., Lipson EJ; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, United States., Gojo I; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States., Lee EJ; Maryland Oncology Hematology, Columbia, MD 21044, United States., Johnson TP; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States., Saidha S; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States., Llinas R; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States., Ostrow LW; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.; Department of Neurology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, United States., Naidoo J; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, United States.; Department of Oncology, Johns Hopkins Bayview Medical Center, Baltimore, MD 21224, United States.; Department of Medicine, Beaumont Hospital Dublin and RCSI University of Health Sciences, Dublin, 9, Ireland., Probasco JC; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.

Publikováno v: The oncologist [Oncologist] 2024 Jul 26. Date of Electronic Publication: 2024 Jul 26.

Randomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDS.

Autor: Gladstone DE; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY., D'Alessio F; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD., Howard C; Department of Medicine, Baylor College of Medicine, Houston, TX., Lyu MA; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Mock JR; Division of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC., Gibbs KW; Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC., Abrams D; Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, and Center for Acute Respiratory Failure, New York-Presbyterian Hospital, New York, NY., Huang M; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Zeng K; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Herlihy JP; Department of Medicine, Baylor College of Medicine, Houston, TX., Castillo ST; Department of Medicine, Baylor College of Medicine, Houston, TX., Bassett R; Department of Biostatistics, MD Anderson Cancer Center, Houston, TX., Sadeghi T; Cellenkos Inc., Houston, TX., Parmar S; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Flowers CR; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Mukherjee S; Division of Hematology/ Oncology, Department of Medicine, New York-Presbyterian Hospital, Columbia University Irving Medical Center, New York, NY., Schoenfeld D; Mass General Hospital, Biostatistics, Boston, MA., Thall PF; Department of Biostatistics, MD Anderson Cancer Center, Houston, TX., Slutsky AS; Keenan Research Center, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto and University of Toronto, Toronto, Canada.

Publikováno v: Blood advances [Blood Adv] 2023 Jul 11; Vol. 7 (13), pp. 3075-3079.

Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.

Autor: Ravandi F; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA. fravandi@mdanderson.org., Kreitman RJ; Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, MD, USA., Tiacci E; Institute of Hematology, Department of Medicine and Surgery, University and Hospital of Perugia, Perugia, Italy., Andritsos L; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA., Banerji V; Department of Internal Medicine & Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.; CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, MB, Canada., Barrientos JC; Feinstein Institutes for Medical Research and Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY, USA., Bhat SA; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA., Blachly JS; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA., Broccoli A; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli'; and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy., Call T; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Chihara D; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dearden C; The Royal Marsden NHS Foundation Trust, London, UK., Demeter J; Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary., Dietrich S; Department of Hematology, University Hospital of Heidelberg, Heidelberg, Germany., Else M; Division of Molecular Pathology, The Institute of Cancer Research, London, UK., Epperla N; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA., Falini B; Institute of Hematology, Department of Medicine and Surgery, University and Hospital of Perugia, Perugia, Italy., Forconi F; School of Cancer Sciences, Cancer Research UK Southampton Centre, Faculty of Medicine, University of Southampton, Southampton, UK.; Haematology Department, Cancer Care Directorate, University Hospital Southampton NHS Trust, Southampton, UK., Gladstone DE; Johns Hopkins Kimmel Cancer Center Baltimore, Baltimore, MD, USA., Gozzetti A; Dept. of Medicine, Surgery and Neurosciences, University of Siena, Policlinico S. Maria alle Scotte-, Siena, Italy., Iyengar S; The Royal Marsden NHS Foundation Trust, London, UK., Johnston JB; Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada., Jorgensen J; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Juliusson G; Lund University Stem Cell Center, Lund, Sweden., Lauria F; University of Siena, Siena, Italy., Lozanski G; Department of Pathology, The Ohio State University Medical Center, Columbus, OH, USA., Parikh SA; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Park JH; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Polliack A; Hadassah University Hospital, Jerusalem, Israel., Quest G; Kingston Health Sciences Centre, Canada, Canada., Robak T; Department of Hematology, Medical University of Lodz, Lodz, Poland., Rogers KA; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA., Saven A; Division of Hematology and Oncology, Scripps Clinic, La Jolla, CA, USA., Seymour JF; Haematology Department, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia., Tadmor T; Hematology Unit, Bnai Zion Medical Center; and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel., Tallman MS; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Tam CS; Department of Haematology, Alfred Hospital and Monash University, Melbourne, Victoria, Australia., Thompson PA; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Troussard X; Department of Hematology, Centre Hospitalier Universitaire Cote de Nacre, Caen, France., Zent CS; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA., Zenz T; Dept. of Medical Oncology and Haematology, University Hospital Zürich and University of Zurich (UZH), Zurich, Switzerland., Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli'; and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy., Wörmann B; The Charité - Universitätsmedizin Berlin, Berlin, Germany., Rai K; Feinstein Institutes for Medical Research and Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY, USA., Grever M; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.

Publikováno v: Blood cancer journal [Blood Cancer J] 2022 Dec 13; Vol. 12 (12), pp. 165. Date of Electronic Publication: 2022 Dec 13.